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Background: Four practice-based research networks (PBRNs) participated in a study to determine whether networks
could increase dissemination, implementation, and diffusion of evidence-based treatment guidelines for chronic
kidney disease by leveraging early adopter practices.
Methods: Motivated practices from four PBRNs received baseline and periodic performance feedback, academic
detailing, and weekly practice facilitation for 6 months during wave I of the study. Each wave I practice then
recruited two additional practices (wave II), which received performance feedback and academic detailing and
participated in monthly local learning collaboratives led by the wave I clinicians. They received only monthly practice
facilitation. The primary outcomes were adherence to primary care-relevant process-of-care recommendations from
the National Kidney Foundation Kidney Disease Outcomes Quality Initiative Guidelines. Performance was determined
retrospectively by medical records abstraction. Practice priority, change capacity, and care process content were
measured before and after the interventions.
Results: Following the intervention, wave I practices increased the use of ACEIs/ARBs, discontinuation of NSAIDs,
testing for anemia, and testing and/or treatment for vitamin D deficiency. Most were able to recruit two additional
practices for wave II, and wave II practices also increased their use of ACEIs/ARBs and testing and/or treatment of
vitamin D deficiency.
Conclusions: With some assistance, early adopter practices can facilitate the diffusion of evidence-based approaches
to other practices. PBRNs are well-positioned to replicate this process for other evidence-based innovations.
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Many practice-based research networks (PBRNs) func-
tion as learning communities that strive to improve
quality of care in member practices [1-4]. Some provide
resources to support dissemination and implementation,
such as performance feedback, identification and spread
of best indigenous practices, academic detailing, and prac-
tice facilitation, evidence-based strategies that have been* Correspondence: james-mold@ouhsc.edu
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unless otherwise stated.tested and refined in Ontario, Canada, the Oklahoma
Physicians Resource/Research Network (OKPRN), and in
other primary care settings [5-11]. Respectful relationships
between the academic detailers and practice facilitators
(PFs), and the practice clinicians and staff, appear to be
critical to success. This principle has also been the key to
the success of Cooperative Extension, in which extension
agents develop relationships with farmers and their
families to facilitate implementation of innovative farm-
ing practices [12].
While this approach to dissemination and implemen-
tation has been successful in practices that volunteer totd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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practices: whether the rate of diffusion can be increased
and whether the cost of implementation assistance can
be reduced. Evidence that peer-to-peer learning can mo-
tivate practice improvement, especially when enhanced
by competition, has led to the development and use of
learning collaboratives [13-15]. These collaboratives typic-
ally involve large numbers of practices and include peri-
odic conferences between periods of local improvement
activities. In OKPRN, researchers working with small rural
practices have adapted this approach, holding shorter
more frequent meetings with a smaller number of prac-
tices [16]. These local learning collaboratives (LLCs) are
less costly and probably better-accepted by clinicians and
staff than the larger, more formal collaboratives [17].
The Agency for Healthcare Quality and Research wanted
to determine whether PBRNs could speed dissemination
and implementation of evidence-based practices. We were
one of the several groups to receive funding for this initia-
tive. We chose to address chronic kidney disease (CKD)
guidelines, since member practices indicated that this was
an area of both weakness and interest. Our goal was to try
to help a group of early-adopter practices implement the
guidelines using standard implementation strategies, then
see whether those practices could recruit and train add-
itional practices using LLCs and less intensive facilitation.
Between the 1988–1994 and the 2003–2006 National
Health and Nutrition Examination Surveys, the preva-
lence of CKD in individuals aged 60 and older increased
from 18.8% to 24.5% [18]. CKD is associated with a 5-year
all-cause mortality rate of 24% and a 20% 5-year require-
ment for transplant or dialysis [19]. Evidence-based guide-
lines for the management of patients with CKD have been
available to practicing physicians since 2002 [20], and
there is some evidence to suggest that guideline-based
care can delay CKD progression and reduce mortality
[13,21-24]. However, dissemination, implementation, and
diffusion of guideline recommendations have been sub-
optimal [16,25,26].
The primary aim of the present study was to deter-
mine the extent to which ‘early adopter’ practices could
facilitate recruitment of other practices and, using the
experience gained during their own implementation ef-
forts, help the new practices to implement guideline rec-
ommendations. Success was measured by numbers of
wave II practices enrolled; numbers of LLCs formed, held,
and attended by wave I practice representatives; and im-
provements in performance by wave II practices. In other
words, we wanted to determine if we could speed up the
diffusion of ‘best practices’ by leveraging the relationships
and resources of practice-based research networks.
The secondary aim was to determine whether the change
processes used by wave II practices would be the same as
or different from those used by the early adopters. Theoutcome measures for this aim were changes in priority for
improvement of CKD care, change process capability, and
care process content, concepts proposed by Solberg [27].
Methods
Study design
This was a cohort study involving primary care practices
enrolled in two waves. Data on practice enrollment, prac-
tice characteristics, and practice change component scores
were captured concurrently. Practice performance data
were collected retrospectively after each wave using med-
ical records abstraction. Additional information was pro-
vided by concurrent facilitator field notes and retrospective
clinician interviews. Four PBRNs participated in the pro-
ject: OKPRN, the Los Angeles Practice-Based Research
Network (LA Net), the Minnesota Academy of Family Phy-
sicians Research Network (MAFPRN), and the Wisconsin
Research and Education Network (WREN). A coordinating
center, Westat, managed the project activities and con-
ducted the data management and analysis.
Each PBRN was asked to recruit eight member prac-
tices (N = 32) to participate in wave I of the study. Since
each network handled this differently, we have no data
on the number of practices who declined to participate.
At the time of enrollment, a clinician from each of these
practices agreed to help the investigators recruit two
additional practices (N = 64) and help to facilitate the
LLC strategy during wave II. Each PBRN provided a
local project coordinator, an academic detailer, and PFs
(1 full-time equivalent) to work directly with the practices,
collect performance data, and, during wave II, organize
the monthly LLC meetings. In addition to practice per-
formance data, surveys completed by a lead clinician from
each practice were used to collect information about the
impact of the implementation and diffusion strategies on
three components of practice change: priority for change,
change process capability, and care process content [28].
Practices were directed to focus on the eight processes
of care emphasized in the National Kidney Foundation
Kidney Disease Outcomes Quality Initiative Guidelines: 1)
making and documenting the diagnosis, 2) ordering appro-
priate tests based upon severity of disease, 3) discontinuing
potentially harmful medications, 4) starting potentially
beneficial medications, 5) managing diabetes and cardio-
vascular disease risk factors, 6) educating patients about
vein preservation, 7) giving appropriate immunizations,
and 8) referring patients with advanced disease to a neph-
rologist [20]. Specific recommendations within each of
these categories were consolidated into a one-page, lami-
nated decision-support tool, which was provided to the
practices and discussed in the academic detailing sessions.
Maintenance of Certification (MOC) Part IV credit was
provided through the American Boards of Family Medicine
and Internal Medicine, which was a significant motivator
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(CME) credit was also provided through the American
Academy of Family Physicians.
The project was approved by the Institutional Review
Boards at the University of Oklahoma Health Sciences
Center, the University of Wisconsin at Madison, the
University of Minnesota, the University of Southern
California Health Sciences Center, and Westat.
Interventions
Wave I
At the start of wave I, practices received performance
evaluation and feedback reports and academic detailing,
followed by weekly practice facilitation for 6 months.
Academic detailing included a review of the guideline
recommendations, a discussion of the one-page decision-
support tool (included as an attachment), a forum to dis-
cuss questions and concerns, a review of the practice’s
current methods and performance, and guidance from the
methods used in high performing practices, culminating
in an agenda for improvement. The PFs were expected to
spend 2–4 h per week in each practice helping clinicians
and staff implement the agreed-upon changes in their care
processes, teaching them how to do quality improvement
(QI) (e.g., plan-do-study-act cycles, QI teams, staff meet-
ings, etc.), and collecting ‘unofficial’ baseline and monthly
performance data for their use. The PBRNs worked with
these practices to recruit and enroll two additional prac-
tices in close geographic proximity to the wave I practices,
and typically belonging to similar health systems or using
an electronic health record (EHR) from the same vendor.
Wave II
Practices in wave II also received performance evalu-
ation and feedback and academic detailing. The three
practices in each cluster (one wave I, two wave II) were
expected to participate in a 1-h LLC meeting each month
to review each other’s performance data, discuss lessons
learned, and share EHR templates, order sets, and other
tools and materials they had discovered or created (e.g.,
patient education handouts). The basic agendas for the
LLC sessions were preset, including review of interim per-
formance data in each participating practice and discus-
sion of successful and unsuccessful approaches tried and
obstacles and opportunities encountered. The first one or
two LLCs often focused on the methods adopted by the
wave I practices, with arrangements for sharing checklists,
templates, and order sets. The PFs generally handled ad-
ministrative aspects of the LLCs, and the wave I clinicians
tended to lead and facilitate the discussions.
During this wave, the PFs spent 2–4 h per month
helping wave II practices implement desired changes in
their care processes, teaching them about QI, and abstract-
ing performance data for QI purposes. Our hope was thatthe assistance provided by wave I practices during the LLC
meetings would reduce the need for PF visits and that
monthly, rather than weekly, visit would be sufficient. This
was based only upon our collective judgment, not on spe-
cific data.
Training and standardization
Training was provided for the academic detailers and
PFs prior to the interventions. The academic detailer
training focused on the guideline recommendations and
suggestions regarding implementation. The PF training
addressed QI concepts, practice facilitation and group fa-
cilitation skills, chart auditing and feedback, the Chronic
Care Model, the nature and behavior of complex adaptive
systems, MOC and CME logistics, and the CKD guidelines
(including the toolkit and implementation suggestions)
and project-related data collection and data transfer. Prior
to wave II, PFs received additional training on the facilita-
tion of LLCs and were provided a sample LLC agenda to
further standardize the experience for the participating cli-
nicians. PFs also participated in training on collection of
the retrospective medical record data upon which these
primary analyses are based.
Practice performance measurement
After completion of each wave, the PFs screened medical
records of diabetic patients between 50 and 84 years of
age to identify at least 30 patients with two estimated
glomerular filtration rates (eGFR) <60, at least 3 months
apart for the next phase of abstraction. If 30 patients
meeting these criteria could not be identified, PFs were
instructed to search the records of patients between 50
and 84 years of age with a diagnosis of hypertension. If 30
patients still could not be identified, PFs were instructed
to identify patients already diagnosed with CKD. The PFs
then abstracted the medical records of patients who had
evidence of CKD to collect information relevant to prac-
tice performance during the specified time periods of
interest. Data on the following were abstracted for every
visit during the qualifying time period: 1) CKD diagnosis
defined as an eGFR staying below 60 for more than
3 months; 2) A1c measurement at least annually, 3) LDL
cholesterol measurement at least annually, 4) microalbu-
min measurement at least annually, 5) Hgb measurement
annually if eGFR <45, 6) ACEI or ARB initiation, 7) dis-
continuation of NSAIDS, 8) vitamin D measurement and/
or initiation of vitamin D supplements if eGFR <45, and
9) referral to a nephrologist for any eGFR <30. We also
examined changes in LDL, A1c, and the mean of the last
three diastolic (DBP) and systolic blood pressures (SBP)
before and after the intervention.
The abstraction windows for wave I practices were the
12 months prior to the beginning of the intervention
(pre-intervention) and the 12 months after the start of
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windows for wave II practices were the 12 months prior
to the beginning of the intervention (pre-intervention)
and the 9 months after the beginning of the intervention
(post-intervention).
Practice contexts and measures of change in priorities
and processes
Data on organizational characteristics (context) were col-
lected from practices upon enrollment. Priority for im-
proving CKD care was measured on a visual analog scale
(CKD priority scale). The instructions read, ‘Considering
all the priorities your clinic has over the next year (e.g.,
EHR, financial goals, QI of various conditions, physician
recruitment), what is the priority for your clinic to im-
prove CKD care (on a scale of 0–10, where 0 = not a prior-
ity, 5 =medium priority, and 10 = highest priority of all)?’
The Change Process Capability Questionnaire (CPCQ),
developed and tested by Solberg [27], was used to meas-
ure organizational factors associated with readiness of
the practice to manage changes needed to implement
guideline recommendations. The instrument includes 30
items measured on a five-point Likert scale, from strongly
agree to strongly disagree. Three domain scores under
organizational factors include ‘previous history of change’,
‘plans for organizational refinement’, and ‘ability to initiate
and sustain change’. The strategies (‘strategy count’) are
specific approaches to managing change, such as periodic
measurement of performance or delegating physician
work to non-physician staff.
The Physician Practice Connections—Patient-Centered
Medical Home Research Version (PPC-PCMH-R), devel-
oped by the National Committee for Quality Assurance,
assessed the implementation of key practice systems for
chronic illness management, including health systems (e.g.,
QI processes), information systems (e.g., registries), deci-
sion support (e.g., structured visits), delivery system design
(e.g., teamwork), and patient self-management support.
Survey data were collected at the beginning and end
of each wave including the priority for improving CKD
care and CPCQ data from the lead clinician, and one
PPC-PCMH-R from each practice. The CPCQ measures
readiness to change and use of various change process
strategies, while the PPC-PCMH-R measures actual prac-
tice systems put into place to achieve better performance
through the use of that readiness and those strategies.
Analytic methods
Except as noted below, all analyses were preplanned.
Descriptive statistics (frequencies and proportions) were
used to describe the wave I and wave II practice charac-
teristics; comparisons between waves were made using
Fisher’s exact test. The proportion of patients with CKD
on the problem list in the pre-intervention period wascompared to the proportion with CKD on the problem
list post-intervention but not pre-intervention. Confi-
dence intervals (CI) were calculated. The proportions of
patients with eGFR <30 who were referred to a neph-
rologist before and after the interventions were similarly
compared. The McNemar test was used to assess changes
in guideline implementation with respect to prescribing
ACEI/ARB, discontinuing NSAIDS and A1c, Hgb, and
vitamin D testing (or supplementation), while the paired
t test was used to assess changes in A1c, SBP and DBP,
and LDL test results.
To account for possible correlation of repeated mea-
sures within patients, a generalized estimating equation
(GEE) approach was used to fit repeated measures models
to assess the pre- to post-intervention change in the im-
plementation of the guideline recommendations. Except
for Hgb and vitamin D measurements, the modeling ana-
lyses were restricted to patients with evidence of CKD
prior to the intervention (at least 3 months of eGFR <60
or documentation of CKD in the problem list). For Hgb
and vitamin D measures, the modeling was further re-
stricted to those subjects with an eGFR <45 in both
periods. Only those patients with outcome information
available during both the pre- and post-intervention pe-
riods contributed to the models. Changes in implementa-
tion of the CKD guidelines were modeled separately for
wave I and wave II practices.
Since preliminary analyses indicated that CKD recog-
nition (CKD reported in the problem list in the medical
record) might have influenced the implementation of the
other guideline recommendations, the models were fit to
the data for each study outcome to assess the effect of
the intervention, adjusted for any influence of when CKD
was recognized and the interaction of the intervention
with CKD recognition, if any (Tables 1 and 2). A signifi-
cant main effect of intervention would indicate that imple-
mentation of the guideline changed significantly over
time, independent of CKD recognition or the timing of
CKD recognition. Assuming the change to be in the de-
sired direction, the result would suggest that the interven-
tion was effective in helping the practices to implement
the guideline. No other variables were included in the
models for this feasibility study.
The initial modeling of the wave II data included all study
practices. However, there were a number of wave II prac-
tices that attended none or very few of the LLC sessions.
These practices would not be expected to benefit from the
diffusion strategy, possibly leading to underestimation of
the effect of the intervention when included. Consequently,
a sub-analysis was conducted on those 30 practices that
participated in at least five LLC sessions to assess the stabil-
ity of the model estimates (sensitivity analysis).
Differences between measures of priority and change
capacity and care processes between baseline and post-
Table 1 Wave I modeling of intervention effect, adjusted for timing of recognition of CKD diagnosis in the medical
record













OR (95% CI) OR (95% CI) OR (95% CI) OR (95% CI) OR (95% CI) OR (95% CI) OR (95% CI)
Intervention effect (post- vs.
pre-intervention)
NA 1.3 (1.1–1.6) 0.7 (0.4–1.0) 1.7 (1.1–2.6) 0.9 (0.7–1.3) 2.6 (1.7–3.8) NA
p value 0.001 0.030 0.014 0.68 <0.0001
CKD recognition: NA NA
Recognized pre-intervention vs.
not recognized
0.9 (0.5–1.6) 0.9 (0.3–2.6) 2.9 (0.9–9.5) 1.1 (0.6–1.9) 0.9 (0.2–3.4)
Recognized post-intervention vs.
not recognized
0.8 (0.4–1.6) 0.8 (0.2–2.6) 2.5 (0.7–8.6) 1.6 (0.9–3.1) 1.0 (0.3–3.9)
Recognized pre-intervention vs.
recognized post-intervention
1.1 (0.7–1.7) 1.2 (0.5–2.7) 1.2 (0.6–2.2) 0.7 (0.4–1.1) 0.9 (0.5–1.7)
p value 0.84 0.92 0.30 0.18 0.95
Interaction of intervention with CKD
recognition:
Post- vs. pre-intervention for CKD
recognized pre-intervention
1.4 (1.0–1.9) 1.6 (1.1–2.1)
Post- vs. pre-intervention for CKD
recognized post-intervention
1.1 (0.8–1.6) 1.2 (0.7–1.9)
Post- vs. pre-intervention for CKD
not recognized
0.6 (0.3–1.0) 0.5 (0.3–0.9)
p value 0.037 0.004
NA not applicable (The main effects contributing to an interaction have different interpretations in the presence of the interaction).
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analyses were carried out using SAS software system,
version 9.2 (SAS Institute Inc., Cary, NC, USA). Imput-
ation for missing values was not considered nor was
there any correction made in the analyses for multiple
comparisons.
Results
Practice participation and characteristics
Across the four PBRNs, 32 practices were recruited for
wave I. One practice had to delay entry into the projectTable 2 Wave II modeling of intervention effect adjusted for
record
Model effects CKD guideline
HbA1c measured
OR (95% CI)
Intervention effect (post- vs. pre-intervention) 1.0 (0.8–1.2)
p value 0.84
CKD recognition: recognized pre-intervention vs.
not recognized
1.4 (0.9–2.2)
Recognized post-intervention vs. not recognized 1.5 (0.9–2.5)
Recognized pre-intervention vs. recognized
post-intervention
0.9 (0.6–1.4)
p value 0.24and was moved to wave II, leaving 31 practices that par-
ticipated in wave I. All wave I practices had been mem-
bers of one of the four PBRNs prior to this project.
Following the wave I implementation intervention, the
31 wave I practices were able to help the research team
recruit and enroll a total of 58 wave II practices (mean:
1.9 per practice). Wave II practices were statistically less
likely to be a member of a PBRN and to have participated
in a QI project before, but they were otherwise similar to
wave I practices with regard to the characteristics exam-
ined. A comparison of wave I and wave II practices, withtiming of recognition of CKD diagnosis in the medical
ACEI/ARB prescribed Taking NSAIDS Vitamin D measured
OR (95% CI) OR (95% CI) OR (95% CI)
1.4 (1.2–1.6) 0.9 (0.7–1.2) 2.2 (1.7–2.9)
<0.001 0.35 <0.0001
1.2 (0.8–1.8) 0.8 (0.4–1.6) 2.3 (0.8–7.0)
1.3 (0.8–2.0) 1.0 (0.5–2.3) 2.5 (0.8–7.9)
1.0 (0.7–1.3) 0.8 (0.4–1.4) 0.9 (0.6–1.5)
0.51 0.67 0.30
Table 3 Practice characteristics by study wave
Characteristic Wave I Wave II p valuec
(N = 31a) (N = 58b)
Outer setting
Practice type: n (%)
Academic practice 3 (10) 5 (10) 0.4
Federally designated health center
or rural clinic
9 (30) 20 (39)
Hospital outpatient practice 5 (17) 6 (12)
Private practice 8 (27) 19 (37)
Other (Free Clinics, etc.) 5 (16) 2 (4)
Missing 1 6
Practice location: n (%)
Rural 11 (38) 15 (29) 0.7
Suburban 6 (21) 14 (27)
Urban 12 (41) 23 (44)
Missing 2 6
Clinician owned: n (%)
Yes 8 (27) 13 (25) 1.0
No 22 (73) 40 (75)
Missing 1 5
PBRN member
Yes 31 (100) 39 (67) 0.0002
No 0 19 (33)
Inner setting
Medical record type: n (%)
EHR 28 (93) 43 (81) 0.2
Paper 2 (7) 10 (19)
Missing 1 5
Number of full-time clinicians: n (%)
1 4 (14) 8 (16) 0.7
2 5 (18) 7 (14)
3–5 10 (36) 12 (24)
≥6 9 (32) 22 (45)
Missing 3 9
Mid-level practitioners: n (%)
Yes 19 (63) 35 (66) 0.8
No 11 (37) 18 (34)
Missing 1 5
Ever in QI project: n (%)
Yes 25 (89) 31 (65) 0.0292
No 3 (11) 17 (35)
Missing 3 10
aOne wave I practice did not provide any baseline information.
bOne wave II practice did not provide any baseline information.
cp values obtained from Fisher’s exact test.
EHR electronic health record, eGFR estimated glomerular filtration rate, QI
quality improvement, PF practice facilitator, LLC local learning collaborative.
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et al., can be found in Table 3 [29].
Twenty of the expected 30 LLCs actually met as
planned. The predominantly inner-city safety net practices
in Los Angeles found it impossible to schedule LLCs and
instead held monthly conference calls to which all partici-
pating practices were invited. In OKPRN, MAFPRN, and
WREN, eight, seven, and seven LLCs were formed and
met a total of 121 times. Wave I clinicians attended 82%
of the LLC meetings.
Wave I practice performance
Wave I practice performance data were obtained from the
medical records of 711 patients. The majority were female
(62%), born prior to 1/1/45 (54%) and thus were Medicare
eligible, and white (78%). Among the 271 patients with
evidence of CKD during the pre-intervention period, 39%
(95% CI: 33%–45%) had CKD in the problem list com-
pared to 66% (95% CI: 62%–70%) of 461 meeting CKD
criteria during the post-period.
Among the 105 patients with eGFR <30 during the
pre-intervention period, 66% (95% CI: 56%–75%) had a re-
ferral to a nephrologist, compared to 71% (95% CI: 62%–
79%) of 124 with eGFR <30 during the post-intervention
period. In the unadjusted analysis, prescription of ACE/
ARBs and testing for Hgb and vitamin D (or supple-
mentation) increased significantly from the pre- to post-
intervention period (Table 4).
The interaction of the intervention with CKD recogni-
tion contributed significantly to predicting the probability
of A1c measurement in the adjusted modeling (p = 0.037),
indicating that the effect of the intervention varied accord-
ing to whether or not CKD was recognized in the patient
and the timing of such (Table 1). Among participants with
CKD recognized in the pre-intervention period, there was
a significantly increased probability of having HbA1c mea-
sured in the post-intervention period compared to the
pre-intervention period (odds ratio (OR) = 1.4, 95% CI:
1.0–1.9). This was also true for the measurement of
microalbumin, with the interaction contributing signifi-
cantly to the model (p = 0.004); participants with CKD
recognized in the pre-intervention period were signifi-
cantly more likely to have microalbumin measured in the
post-intervention period compared to the pre-intervention
period (OR = 1.6, 95% CI: 1.1–2.1).
The modeling results indicate that the probability of
being prescribed ACEIs/ARBs and having Hgb and vita-
min D measured (or vitamin D supplements given) in-
creased significantly from pre- to post-intervention (OR =
1.3, 95% CI: 1.1–1.6, p = 0.001; OR = 1.7, 95% CI: 1.1–2.6,
p = 0.014; and OR = 2.6, 95% CI: 1.7–3.9, p <0.0001, re-
spectively), but that the probabilities did not differ accord-
ing to whether or not CKD was recognized or the timing
of such (p ≥0.30). The odds of being on NSAIDS was
Table 4 CKD performance outcome measures for wave I and wave II practices










If eGFR <60 N = 374 N = 660
ACE or ARB prescribed: n (%) 232 (63%) 255 (69%) 0.002 354 (55%) 407 (63%) <0.001
Taking NSAIDs: n (%) 25 (7%) 18 (5%) 0.10 51 (8%) 45 (7%) 0.44
A1c testing performed: n (%) 288 (77%) 297 (79%) 0.25 492 (89%) 487 (88%) 0.65
Urine microalbumin test
performed: n (%)
158 (42%) 175 (47%) 0.16 NA NA NA
LDL test performed: n (%) 309 (83%) 305 (82%) 0.75 NA NA NA
A1c test results: Mean (SD) 7.1% (1.4) 7.2% (1.5) 0.78 7.4% (1.6) 7.3% (1.5) 0.07
Systolic BP measure (mmHg):
mean (SD)
132.5 (16.3) 132.8 (16.0) 0.72 132.0 (15.9) 131.4 (14.9) 0.39
Diastolic BP measure (mmHg):
mean (SD)
72.8 (9.1) 72.7 (9.0) 0.93 72.0 (9.4) 71.7 (8.5) 0.48
LDL test result (mg/dl):
mean (SD)
89.8 (36.6) 90.2 (32.8) 0.84 96.3 (38.1) 92.0 (34.5) 0.004
If eGFR <45 N = 138 N = 233
Hemoglobin test performed:
n (%)
84 (61%) 100 (72%) 0.02 NA NA NA
Vitamin D testing (or
supplement): n (%)
51 (37%) 83 (60%) <0.001 87 (37%) 132 (57%) <0.001
SD standard deviation, NA not applicable because it was an annual recommendation and in wave II, the post-intervention period was only 9 months.
*McNemar’s test was used to generate p values for categorical-scaled outcomes and the paired t test for continuous-scaled outcome measures.
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pared to the pre-intervention period (OR = 0.7, 95% CI:
0.4–0.95; p = 0.030) but did not differ according to
whether or not CKD was recognized or the timing of
such (p = 0.92).
Wave II practice performance
For Wave II, data were abstracted on 1,179 patients. The
majority were female (63%), Medicare eligible (60%) and
white (78%), similar to wave I patients. Among the 466 pa-
tients with evidence of CKD during the pre-intervention
period, 41% (95% CI: 37%–45%) had CKD in the problem
list compared to 58% (95% CI: 54%–62%) of 664 with
CKD evidence during the post-intervention period.
Among the 129 patients with any eGFR <30 during
the pre-intervention period in wave II, 60% (95% CI: 51%–
68%) had a referral to a nephrologist, compared to 55%
(95% CI: 47%–63%) of 176 patients with eGFR <30 first
documented during the post-intervention period. The pre-
scription of ACEI/ARBs and testing for vitamin D (or sup-
plementation) among those with eGFRs <45 increased
significantly post-intervention (Table 4).
In the adjusted modeling, the probability of having
Hgb measured did not differ significantly from zero (no
change pre- to post-intervention) (OR = 0.8, 95% CI:
0.6–1.2, p = 0.38), but did differ in relation to CKD recog-
nition (p = 0.009) (Table 2). Patients with CKD recognized
in the pre-intervention period were significantly less likelyto have Hgb measured in the post-intervention period
compared to pre-intervention period than those with
CKD recognized in the post-intervention period (OR =
0.4, 95% CI: 0.2–0.8; p = 0.006).
The probability of being prescribed ACEIs/ARBs in-
creased significantly from pre- to post-intervention (OR =
1.4, 95% CI: 1.2–1.6; p <0.0001), as did measurement of
vitamin D (or vitamin D supplements given) (OR = 2.2,
95% CI: 1.7–2.9; p <0.0001) (Table 2). The probability of
implementation of these guidelines did not differ accord-
ing to whether or not CKD was recognized or the timing
of such (p ≥0.3). The probability of having microalbumin
measured increased from the pre- to post-intervention
period, but the change was of only borderline significance
(OR = 1.2, 95% CI: 1.0–1.5; p = 0.069). CKD recognition
did not contribute to predicting the change in microalbu-
min measurement (p = 0.36).
Sub-analyses were conducted on those 30 practices that
attended at least five LLC sessions; ten practices attended
five (all included wave I staff members) and 20 practices
attended six (12 wave I practice staff members attended
six; eight attended five). These analyses included 387 sub-
jects with information available during the pre- and post-
intervention periods; this number was further reduced to
125 subjects for the Hgb and vitamin D modeling which
required eGFR to be <45. As was true for the original wave
II modeling, the prescribing of ACEIs/ARBs increased
significantly for the post-intervention period compared to
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1.3, 95% CI: 1.1–1.5, p = 0.005), as did measurement of
vitamin D (OR = 2.4, 95% CI: 1.7–3.4, p <0.0001). Meas-
urement of A1c (p = 0.81), Hgb (p = 0.84), and microalbu-
min (p = 0.67) did not differ significantly according to the
study period in either modeling or did the use of NSAIDS
(p = 0.68).Changes in eGFR
No significant changes were seen in mean eGFRs be-
tween the pre- and post-intervention periods for patients
in either wave. Mean (SD) eGFRs for wave I patients
were 42.3 (11.9) pre-intervention and 42.1 (12.9) post-
intervention (p = 0.71). Mean eGFRs for wave II patients
were 43.9 (11.1) pre-intervention and 43.2 (11.9) post-
intervention (p = 0.06).Practice process changes
For wave I practices, priority for improving care of pa-
tients with CKD remained relatively high, with no
significant change from pre- to post-intervention, and
there was no significant change in subscales designed to
measure organizational factors associated with practice
change capacity (i.e., history of change, continuous re-
finement, and sustaining change), but the use of change
strategies increased (Table 5). A similar pattern of find-
ings occurred in wave II, including a significant increase
in strategy count. There was, however, no statistically
significant increase in practice systems in wave II prac-
tices, but their baseline scores were also higher.Table 5 Pre- and post-intervention priority, change capacity,
Instrument Wave I
n Pre-intervention Post-interv
Mean (SD) Mean (SD)
Priority for improving CKD care 28 6.1 (2.4) 6.4 (2.1)
CPCQ:
Organizational factors 26 14.5 (11.4) 16.8 (9.0)
Previous history of change 28 2.4 (3.1) 3.2 (2.3)
Plans for organizational refinement 29 3.6 (2.6) 4.2 (1.7)
Ability to initiate and sustain change 26 8.3 (6.7) 9.4 (6.2)
Strategy count 25 3.3 (4.1) 18.6 (4.5)
PPC-PCMH-R:
Health systems 28 45.8 (32.3) 50.0 (30.8)
Clinical information system 28 48.8 (16.0) 56.3 (16.5)
Decision support 28 45.8 (17.1) 63.3 (19.6)
Delivery system design 25 25.0 (14.8) 34.8 (22.7)
Patient self-management support 28 21.8 (12.5) 32.1 (16.8)
*The paired t test was used to generate the p values.
SD standard deviation, CPCQ Change Process Capability Questionnaire, PPC-PCMH P
Research Version.Discussion
In their comprehensive review of innovation diffusion,
Greenhalgh et al. identified a number of unanswered ques-
tions including, ‘Is there a role for a central agency, resource
center, or officially sanctioned demonstration programs?
and What is (or could be) the role of professional organiza-
tions and informal inter-professional networks in spreading
innovation among health care organizations?’ [30] The re-
sults of this study suggest that diffusion, which is generally
considered to be a passive process, can be facilitated by
PBRN researchers and member practices using a combin-
ation of assistance and incentives. Whether PBRNs should
assume this role or whether a broader extension system
similar to cooperative extension in agriculture should be
developed for this purpose remains open [31,32]. In either
case, PBRNs are likely to be a source of early adopter prac-
tices and possibly clinician opinion leaders.
Our results also speak to a second question posed by
the Greenhalgh review, ‘What is the nature of the net-
works, of different players… [and] How do these networks
serve as channels for …embedding of complex service in-
novations?’ Most of the early adopters chose to recruit
practices with similar characteristics—either members of
the same health system or those that used the same EHR.
Reducing the complexity of the implementation setting is
likely to facilitate adoption; furthermore, health system ad-
ministrators often must approve efforts such as these that
require templates and order sets.
As expected, the combination of performance feed-
back (baseline and monthly), academic detailing, and
weekly PF for 6 months resulted in improved recognitionand change process content scores
Wave II
ention p value* n Pre-intervention Post-intervention p value*
Mean (SD) Mean (SD)
0.46 39 6.0 (2.1) 6.4 (1.90) 0.27
0.29 39 13.2 (9.8) 15.0 (7.9) 0.25
0.25 39 2.4 (2.3) 2.5 (2.5) 0.95
0.21 40 3.0 (2.7) 3.7 (2.0) 0.08
0.43 40 8.0 (5.9) 9.1 (4.8) 0.22
<0.0001 37 5.5 (7.8) 16.7 (7.9) <0.0001
0.27 28 41.1 (28.9) 40.5 (31.2) 0.90
0.016 28 53.2 (16.2) 58.9 (20.2) 0.12
0.0001 28 52.8 (18.4) 60.5 (24.5) 0.14
0.013 28 32.8 (18.6) 34.4 (20.0) 0.73
0.005 28 26.5 (17.4) 30.8 (18.6) 0.23
hysician Practice Connections—Patient-Centered Medical Home
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demonstrated improvements in the use of ACEIs and
ARBs, measurement of Hgb, and vitamin D testing or sup-
plementation. Since diabetes care had received a great deal
of attention already, baseline adherence to those measures
was high in many practices. Likewise, rates of usage of
NSAIDs were already low. It is also important to remem-
ber that 100% adherence is not an appropriate expect-
ation, since guidelines do not apply to all patients with
CKD, and we did not exclude patients with, for example,
terminal illness, dementia, or contraindications to particu-
lar strategies. The interventions resulted in development
of both new strategies (techniques) and new processes of
care (system level changes).
Wave II practices showed improvements in care of
their CKD patients similar to wave I practices with less
PF assistance. This is important since PF support is rela-
tively expensive. As in wave I, the interventions resulted
in the development of new strategies, but there was no
significant increase in new processes of care. However,
wave II practices had less time (9 vs. 12 months) to
change, and their baseline process scores were nearly as
high as the post-intervention process scores for wave I
practices, leaving less room for improvement. This could
have, in part, been due to cross-contamination within
health systems that chose to implement system wide
changes prior to wave II.
We are optimistic that many of the new processes im-
plemented during this project will be sustained since
they were typically accompanied by the creation of tem-
plates, order sets, and other modifications to the EHRs.
The automatic calculation of eGFR by the labs used by
participating practices prior to or as a result of the pro-
ject, and the increased awareness of the importance of
eGFR created by the project are also likely to persist.
However, at this point, we have no data upon which to
assess sustainability. Despite the availability of EHR
options like templates and order sets, the one-page
summary of guideline recommendations organized by
CKD stage and substage proved to be very helpful to
practices as they developed strategies for improvement
(see Additional file 1). Many practices reported putting
them in exam rooms and referring to them routinely.
The one-page summary was also provided to several
practices not involved in the project upon request after
having heard about it from colleagues. This we found
interesting, since, in theory, all of this could be pro-
grammed into an EHR.
We found evidence that putting CKD on the problem
list is a critical first step in providing evidence-based
care for patients with CKD. Guideline producers should
consider developing both practice-friendly summaries
and suggestions regarding implementation sequencing.
This would require collaboration with end-users (practices)and implementation researchers. PBRNs could be helpful
in this role.
This study has several limitations. It was designed to
determine whether experienced practices could facilitate
improvements in other practices. A separate control group
was not included. Therefore, a secular trend toward better
care of CKD patients could have contributed to observed
performance improvements. However, practices engaged in
the project uniformly indicated that they had done little to
improve their care of patients with CKD prior to the pro-
ject, and we know of no attempts by others in the involved
states to address this problem during the project. Likewise,
we are unaware of changes in medication cost or availabil-
ity that might have resulted in increased prescribing of
ACEIs or ARBs, though that is certainly a possibility.
Due to delays in recruitment and enrollment of wave
II practices and the prohibition on no-cost extensions
imposed by the American Recovery and Reinvestment
Act, the length of the wave II post-intervention period
was shortened from 12 months (as in wave I) to 9 months.
As a result, improvement in measures of guideline adher-
ence requiring annual testing (e.g., measurement of lipids,
anemia tests, and microalbumin) may be underestimated.
Wave II practices also had less time to implement sys-
tem level changes which could have reduced the impact
of the intervention.
We anticipated abstracting data on 30 patients from
each participating practice. Unfortunately, practices var-
ied widely in their ability to identify patients with two
eGFRs <60 at least 3 months apart. Therefore, the num-
ber of patients from practices eligible for these analyses
ranged from 1 to 27, making it impossible to adjust for
variation among practices. Although the smaller than ex-
pected sample reduced the statistical power of our ana-
lyses, we were nevertheless able to demonstrate significant
improvements in guideline implementation by both wave
I and wave II practices.
Conclusions
After receiving implementation assistance, early adopter
practices were able to help to recruit and support add-
itional practices with implementation of the National
Kidney Foundation Kidney Disease Outcomes Quality
Initiative CKD guidelines through monthly LLCs, per-
formance feedback (baseline and monthly), academic de-
tailing, and monthly practice facilitation over a 6-month
period. This may be an important way to disseminate, im-
plement, and diffuse other evidence-based innovations.Additional file
Additional file 1: Summary of CKD guideline recommendations for
primary care (updated).
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